Table 1A.
Development status of therapeutic mAbs targeting GPCRs
| Target | Name | Company | Therapeutic Indication | Clinical Status |
|---|---|---|---|---|
| Humanized | ||||
| CCR4 | Mogamuli zumab | Amgen/Kiowa Hakko Kirin | Leukemia, Lymphoma/Asthma | Phase I/II Approved in Japan for relapsed or refractory T cell leukemia and lymphoma |
| Human | ||||
| C3aR | Human Genome Sciences | Asthma | Preclinical | |
| C5aR | NN-8209 | G2 Therapies/Novo Nordisk | Autoimmune Disease | Phase I |
| CCR2 | MLN1202 | Takeda | Inflammation | Phase II- Discontinued |
| CCR4 | AT0009 | Affitech | Cancer | Pre-clinical |
| CCR5 | PRO140 | Progenics | HIV | Phase 2- Discontinued |
| CCR5 | HGS004 | Human Genome Sciences | HIV | Phase I- Discontinued |
| CCR5 | HGS101 | Human Genome Sciences | HIV | Discontinued |
| CCR8 | X | Lilly | Inflammation | Undisclosed |
| CCR9 | MLN3126 | Takeda | Inflammatory Bowel Disease | Discontinued |
| CRTH2 | Sosei/Abgenix | Inflammation | No Information | |
| CXCR3 | AT0010 | Affitech | Inflammation | Discovery |
| CXCR4 | MDX 1338 | Medarex/BMS | Leukemia | Phase I |
| CXCR4 | ALX-0651 | Ablynx | Cancer | Phase I- Discontinued |
| CXCR4 | LY2624587 | Lilly | Cancer | Phase I- Discontinued |
| GCG-R | AMG477 | Amgen | Diabetes | Phase I- Discontinued |
| GLP-1R | X | Abbott/Human Genome Sciences | Diabetes/Neurologic/Metabolic Disease | No information |
| LGR5 | KM4056 | Kiowa Hakko Kirin | Cancer | Pre-clinical |
| VPAC-1 | Thrombogenics | Thrombocytopenia | Pre-clinical | |
The list in the table above should not be considered exhaustive; we have used the databases listed below to update and add to information published in [8]. They are the following: www.imgt.org/mAb-DB/index#Human; www.Alxn.com; www.kyowa-kirin.co.jp/english; www.gsk.com; www.janssenrnd.com; www.lilly.com; www.amgen.com; www.hgsi.com; www.abbott.com; www.tpna.com; www.sosei.com; www.affitech.com; clinicaltrials.gov; https://eudract.ema.europa.eu